BMS-986504 + [14C]-BMS-986504
Phase 1Recruiting 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Solid Tumors With Homozygous MTAP Deletion
Conditions
Advanced Solid Tumors With Homozygous MTAP Deletion
Trial Timeline
Mar 24, 2025 → Apr 20, 2026
NCT ID
NCT06672523About BMS-986504 + [14C]-BMS-986504
BMS-986504 + [14C]-BMS-986504 is a phase 1 stage product being developed by Bristol Myers Squibb for Advanced Solid Tumors With Homozygous MTAP Deletion. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06672523. Target conditions include Advanced Solid Tumors With Homozygous MTAP Deletion.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Solid Tumors With Homozygous MTAP Deletion were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
6
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06672523 | Phase 1 | Recruiting |
Competing Products
20 competing products in Advanced Solid Tumors With Homozygous MTAP Deletion